It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Viking Therapeutics seems to be doubling down on its hopes of making waves in the weight management market as a stand-alone ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

Viking is in the midst of a Phase 2a dosing trial of VK2735, with a data readout expected in the second half of the year. The company is expected to launch a Phase 3 trial of VK2735 in injectable ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ...

Is the Street right to place such high hopes on this company. Viking Therapeutics' leading candidate, VK2735, is a weight loss medicine. Many pharmaceutical giants are looking to enter this market ...